Pharma

Your Article Summary

See Latest Articles

Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
Amylin Pharmaceuticals, 05/06/09

Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. announced that a New Drug Application for exenatide once weekly has been submitted to the U.S. Food and Drug Administration. Exenatide once weekly is an investigational sustained release medication for type 2 diabetes that is injected subcutaneously and administered only once a week. Exenatide is the active ingredient in BYETTA injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to achieve good glycemic control with common oral therapies.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals